Terms: = Ovarian cancer AND TLX1, P31314, 3195, ENSG00000107807, TCL3, HOX11
6 results:
1. HIPEC in ovarian cancer: When and to Whom?
Ates O; Aksel B; Akkus MH; Oner I; Yuksel C; Dogan M
J Coll Physicians Surg Pak; 2023 Sep; 33(9):1001-1005. PubMed ID: 37691361
[TBL] [Abstract] [Full Text] [Related]
2. Preoperative serum microRNAs as potential prognostic biomarkers in ovarian clear cell carcinoma.
Suzuki K; Yokoi A; Yoshida K; Kato T; Ochiya T; Yamamoto Y; Kajiyama H
J Gynecol Oncol; 2023 May; 34(3):e34. PubMed ID: 36603851
[TBL] [Abstract] [Full Text] [Related]
3. A meta-analysis on the diagnostic value of diffusion-weighted imaging on ovarian cancer.
Dai G; Liang K; Xiao Z; Yang Q; Yang S
J BUON; 2019; 24(6):2333-2340. PubMed ID: 31983103
[TBL] [Abstract] [Full Text] [Related]
4. Prevalence and spectrum of BRCA germline variants in mainland Chinese familial breast and ovarian cancer patients.
Kim YC; Zhao L; Zhang H; Huang Y; Cui J; Xiao F; Downs B; Wang SM
Oncotarget; 2016 Feb; 7(8):9600-12. PubMed ID: 26848529
[TBL] [Abstract] [Full Text] [Related]
5. PAX-2 expression in non-neoplastic, primary neoplastic, and metastatic neoplastic tissue: A comprehensive immunohistochemical study.
Zhai QJ; Ozcan A; Hamilton C; Shen SS; Coffey D; Krishnan B; Truong LD
Appl Immunohistochem Mol Morphol; 2010 Jul; 18(4):323-32. PubMed ID: 20216401
[TBL] [Abstract] [Full Text] [Related]
6. Long-term results of therapy for stage C neuroblastoma.
Halperin EC
J Surg Oncol; 1996 Nov; 63(3):172-8. PubMed ID: 8944061
[TBL] [Abstract] [Full Text] [Related]
